

Carlos Rodriguez-Galindo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3525873/publications.pdf>

Version: 2024-02-01

274
papers

13,370
citations

23500

58
h-index

29081

104
g-index

288
all docs

288
docs citations

288
times ranked

13726
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Functional Significance of TP53 Exon 4 Intron 4 Splice Junction Variants. <i>Molecular Cancer Research</i> , 2022, 20, 207-216.	1.5	4
2	Resilient health care in global pediatric oncology during the COVID-19 pandemic. <i>Cancer</i> , 2022, 128, 797-807.	2.0	10
3	Doxorubicin in combination with cisplatin, 5-fluorouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study. <i>Cancer</i> , 2022, 128, 1057-1065.	2.0	14
4	Impact of the COVID-19 pandemic on pediatric oncology providers globally: A mixed-methods study. <i>Cancer</i> , 2022, 128, 1493-1502.	2.0	17
5	Impact of treatment refusal and abandonment on survival outcomes in pediatric osteosarcoma in Southeast Asia: A multicenter study. <i>Pediatric Blood and Cancer</i> , 2022, , e29556.	0.8	1
6	Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. <i>Journal of Clinical Oncology</i> , 2022, 40, 459-467.	0.8	12
7	Subsequent Malignant Neoplasm of Bone in Children and Adolescent: Possibility of Multimodal Treatment. <i>Current Oncology</i> , 2022, 29, 1001-1007.	0.9	3
8	Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage. <i>JCO Global Oncology</i> , 2022, 8, e2100266.	0.8	2
9	Predictors and Treatment Outcomes of Pediatric Osteosarcoma in Diverse Socioeconomic Backgrounds in Southeast Asia: A Retrospective Multicenter Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 631-640.	0.5	0
10	Rhabdomyosarcoma in low- and middle-income countries: A report from the Asociacion de Hematología y Oncología Pediátrica de Centro América (AHOPCA). <i>Pediatric Blood and Cancer</i> , 2022, , e29669.	0.8	0
11	Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol. <i>Implementation Science Communications</i> , 2022, 3, .	0.8	5
12	Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). <i>Journal of Clinical Oncology</i> , 2022, 40, 3839-3847.	0.8	11
13	How Telemedicine and Centralized Care Changed the Natural History of Retinoblastoma in a Developing Country. <i>Ophthalmology</i> , 2021, 128, 130-137.	2.5	30
14	Creation of a successful multidisciplinary course in pediatric neuro-oncology with a systematic approach to curriculum development. <i>Cancer</i> , 2021, 127, 1126-1133.	2.0	6
15	Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. <i>Cancer</i> , 2021, 127, 193-202.	2.0	8
16	Intra-arterial chemotherapy for rhabdomyosarcoma. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 391-396.	0.3	1
17	Development, Implementation, and Outcomes of a Global Infectious Disease Training Course. <i>Journal of Medical Education and Curricular Development</i> , 2021, 8, 238212052110152.	0.7	3
18	The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. <i>Cancer Research</i> , 2021, 81, 2442-2456.	0.4	9

#	ARTICLE	IF	CITATIONS
19	The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28962.	0.8	8
20	Clinical and organizational risk factors for mortality during deterioration events among pediatric oncology patients in Latin America: A multicenter prospective cohort. <i>Cancer</i> , 2021, 127, 1668-1678.	2.0	24
21	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. <i>Ecanermedscience</i> , 2021, 15, 1187.	0.6	4
22	Clinician Emotions Surrounding Pediatric Oncology Patient Deterioration. <i>Frontiers in Oncology</i> , 2021, 11, 626457.	1.3	14
23	Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29018.	0.8	11
24	The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. <i>Blood</i> , 2021, 138, 1677-1690.	0.6	20
25	Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 332-340.	2.7	83
26	Pediatric cancer communication in Guatemala.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18508-e18508.	0.8	0
27	The evolution of parents' beliefs about childhood cancer during diagnostic communication: a qualitative study in Guatemala. <i>BMJ Global Health</i> , 2021, 6, e004653.	2.0	7
28	A sustainable model for pediatric oncology nursing education and capacity building in Latin American hospitals: Evolution and impact of a nurse educator network. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29095.	0.8	5
29	Impact of PEWS on Perceived Quality of Care During Deterioration in Children With Cancer Hospitalized in Different Resource-Settings. <i>Frontiers in Oncology</i> , 2021, 11, 660051.	1.3	14
30	Distal Tibial Reconstruction in the Management of Primary Bone Tumors in Children and Adolescents. <i>Foot and Ankle International</i> , 2021, 42, 107110072110126.	1.1	2
31	Ewing sarcoma: investigational mono- and combination therapies in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 653-663.	1.9	6
32	Clinical features and treatment of Langerhans cell histiocytosis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 2892-2902.	0.7	18
33	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 2463-2473.	0.8	38
34	Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age. <i>Journal of Clinical Oncology</i> , 2021, 39, 2676-2684.	0.8	4
35	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29282.	0.8	3
36	Reply to J.-G. Wang et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 3088-3089.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. <i>Journal of Pediatrics</i> , 2021, 237, 65-70.e3.	0.9	8
38	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1416-1426.	5.1	93
39	Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2021, 128, 317.	2.0	3
40	Communication Priorities and Experiences of Caregivers of Children With Cancer in Guatemala. <i>JCO Global Oncology</i> , 2021, 7, 1529-1536.	0.8	5
41	Adrenocortical Tumors in Children With Constitutive Chromosome 11p15 Paternal Uniparental Disomy: Implications for Diagnosis and Treatment. <i>Frontiers in Endocrinology</i> , 2021, 12, 756523.	1.5	2
42	Evaluation of Early Treatment Response Utilizing the MAS-ALL18 Adapted Management Guideline in Four "Mexico in Alliance with St. Jude" (MAS) Member Hospitals. <i>Blood</i> , 2021, 138, 1210-1210.	0.6	4
43	Molecular and MRD-Based Characterization of Acute Lymphoblastic Leukemia in Mexico: Experience from the "Mexico in Alliance with St. Jude" "Bridge Project". <i>Blood</i> , 2021, 138, 1209-1209.	0.6	1
44	Cancer care for children in the Gaza Strip. <i>Lancet Oncology</i> , The, 2021, 22, 1667-1668.	5.1	3
45	Cancer care for displaced children from Venezuela. <i>Lancet Oncology</i> , The, 2021, 22, 1665-1666.	5.1	1
46	Paediatric Oncology System Integration Tool (POSIT) for the joint analysis of the performance of childhood cancer programs and health systems. <i>Journal of Cancer Policy</i> , 2020, 23, 100208.	0.6	4
47	Pediatric Solid Tumors. , 2020, , 1703-1747.e11.		7
48	Training pediatric hematologist/oncologists for capacity building in Ethiopia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28760.	0.8	6
49	Pediatric cancer communication in low- and middle-income countries: A scoping review. <i>Cancer</i> , 2020, 126, 5030-5039.	2.0	18
50	Interdisciplinary care of pediatric oncology patients in Central America and the Caribbean. <i>Cancer</i> , 2020, 127, 2579-2586.	2.0	4
51	Assessment of Retinoblastoma Capacity in the Middle East, North Africa, and West Asia Region. <i>JCO Global Oncology</i> , 2020, 6, 1531-1539.	0.8	4
52	Qualitative Study of Pediatric Early Warning Systems™ Impact on Interdisciplinary Communication in Two Pediatric Oncology Hospitals With Varying Resources. <i>JCO Global Oncology</i> , 2020, 6, 1079-1086.	0.8	24
53	The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-EE, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28409.	0.8	113
54	Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28327.	0.8	93

#	ARTICLE	IF	CITATIONS
55	XAF1 as a modifier of p53 function and cancer susceptibility. <i>Science Advances</i> , 2020, 6, eaba3231.	4.7	37
56	Pediatric adrenocortical tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101448.	2.2	29
57	Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. <i>Cancers</i> , 2020, 12, 506.	1.7	17
58	Bridging the Gap in Access to Care for Children With CNS Tumors Worldwide. <i>JCO Global Oncology</i> , 2020, 6, 583-584.	0.8	10
59	Sustainable care for children with cancer: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2020, 21, e185-e224.	5.1	177
60	Langerhans cell histiocytosis. <i>Blood</i> , 2020, 135, 1319-1331.	0.6	173
61	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	0.8	101
62	Political priority and pathways to scale-up of childhood cancer care in five nations. <i>PLoS ONE</i> , 2019, 14, e0221292.	1.1	22
63	Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas. <i>Journal of Global Oncology</i> , 2019, 5, 1-7.	0.5	3
64	Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27929.	0.8	220
65	Î±-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. <i>Cancer</i> , 2019, 125, 3649-3656.	2.0	10
66	Cost-benefit analysis of implementing a pediatric early warning system at a pediatric oncology hospital in a low- to middle income country. <i>Cancer</i> , 2019, 125, 4052-4058.	2.0	30
67	Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. <i>Journal of Clinical Oncology</i> , 2019, 37, 2875-2882.	0.8	33
68	Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3369-3376.	0.8	40
69	Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. <i>Blood</i> , 2019, 133, 1691-1694.	0.6	76
70	Things that matter: Adolescent and young adult patients' priorities during cancer care. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27883.	0.8	22
71	Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 396-402.	0.8	11
72	Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 719-727.	5.1	62

#	ARTICLE	IF	CITATIONS
73	Spatial trends in congenital malformations and stream water chemistry in Southern Brazil. <i>Science of the Total Environment</i> , 2019, 650, 1278-1291.	3.9	11
74	Childhood cancer burden: a review of global estimates. <i>Lancet Oncology</i> , The, 2019, 20, e42-e53.	5.1	237
75	Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27469.	0.8	7
76	Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10022-10022.	0.8	1
77	Carcinomas in the children and young adults: A report form Children's Oncology Group APEC14B1 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21505-e21505.	0.8	2
78	Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10036-10036.	0.8	0
79	Maintenance treatment with trofosfamide in patients with primary bone ewing sarcoma - single center experience. <i>Medycyna Wieku Rozwojowego</i> , 2019, 23, 39-44.	0.2	1
80	Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusionâ€“negative rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2018, 124, 1973-1981.	2.0	14
81	The Toronto Guidelines: a practical means for childhood cancer staging. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 158-159.	2.7	3
82	Displaced children with cancer in Lebanon: A sustained response to an unprecedented crisis. <i>Cancer</i> , 2018, 124, 1464-1472.	2.0	22
83	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCHâ€“associated neurodegeneration and mass lesions. <i>Cancer</i> , 2018, 124, 2607-2620.	2.0	73
84	Pediatric Early Warning Systems aid in triage to intermediate versus intensive care for pediatric oncology patients in resourceâ€“limited hospitals. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27076.	0.8	14
85	Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26913.	0.8	16
86	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. <i>Blood</i> , 2018, 131, 2877-2890.	0.6	335
87	Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27111.	0.8	11
88	Global efforts toward the cure of childhood acute lymphoblastic leukaemia. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 440-454.	2.7	83
89	Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26784.	0.8	59
90	Treatment of Relapsed and Refractory Langerhans Cell Histiocytosis in Children. , 2018, , 119-137.		0

#	ARTICLE	IF	CITATIONS
91	Influence of early phase clinical trial enrollment on patterns of end-of-life care for children with advanced cancer. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26748.	0.8	12
92	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1044.	0.8	108
93	Improving Immunohistochemistry Capability for Pediatric Cancer Care in the Central American and Caribbean Region: A Report From the AHOPCA Pathology Working Group. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	4
94	Global Access to Essential Medicines for Childhood Cancer: A Cross-Sectional Survey. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	17
95	Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. <i>European Journal of Cancer</i> , 2018, 98, 30-37.	1.3	38
96	Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?. <i>Gynecologic Oncology</i> , 2018, 150, 253-260.	0.6	21
97	Pediatric Langerhans Cell Histiocytosis (LCH) Clinical Outcome in Hospital Civil De Guadalajara, MÃ©xico. <i>Blood</i> , 2018, 132, 4951-4951.	0.6	1
98	Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors. <i>Blood</i> , 2018, 132, 3684-3684.	0.6	2
99	Rate of MYC-N gene amplification among children of Middle Eastern descent with neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22507-e22507.	0.8	1
100	The cost and cost-effectiveness of a pediatric cancer unit (PCU) in the context of universal health coverage (UHC): A report from the Childhood Cancer 2030 Network.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18891-e18891.	0.8	0
101	Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee. <i>Cancer</i> , 2017, 123, 2360-2367.	2.0	53
102	Delivery of radiation therapy in resource-limited settings: A pilot quality assessment study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26480.	0.8	3
103	Improved outcomes after successful implementation of a pediatric early warning system (PEWS) in a resource-limited pediatric oncology hospital. <i>Cancer</i> , 2017, 123, 2965-2974.	2.0	67
104	Malignant glomus tumors of the head and neck in children and adults: Evaluation and management. <i>Laryngoscope</i> , 2017, 127, 2873-2882.	1.1	15
105	Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors. <i>Cancer</i> , 2017, 123, 3150-3158.	2.0	26
106	Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26394.	0.8	18
107	Addressing regional disparities in pediatric oncology: Results of a collaborative initiative across the Mexican-North American border. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26387.	0.8	15
108	Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26375.	0.8	12

#	ARTICLE	IF	CITATIONS
109	Validation of a pediatric early warning system for hospitalized pediatric oncology patients in a resource-limited setting. <i>Cancer</i> , 2017, 123, 4903-4913.	2.0	56
110	Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 72-77.	0.8	42
111	Socioeconomic status and global variations in the incidence of neuroblastoma: call for support of population-based cancer registries in low-middle-income countries. <i>Pediatric Blood and Cancer</i> , 2017, 64, 321-323.	0.8	19
112	A longitudinal investigation of parenting stress in caregivers of children with retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26279.	0.8	14
113	A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26325.	0.8	19
114	Racial and Ethnic Disparities in the Incidence of Pediatric Extracranial Embryonal Tumors. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	26
115	Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 1203-1210.	0.8	20
116	Death Within 1 Month of Diagnosis in Childhood Cancer: An Analysis of Risk Factors and Scope of the Problem. <i>Journal of Clinical Oncology</i> , 2017, 35, 1320-1327.	0.8	43
117	Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 3465-3473.	0.8	47
118	Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3956-3963.	0.8	33
119	Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10506-10506.	0.8	20
120	Successful Implementation of a Pediatric Early Warning Score in a Resource-Limited Pediatric Oncology Hospital in Guatemala. <i>Journal of Global Oncology</i> , 2016, 2, 60s-60s.	0.5	3
121	Risk of second gonadal cancers in women and children with germ cell tumors. <i>Cancer</i> , 2016, 122, 2076-2082.	2.0	3
122	An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome?. <i>Pediatric Blood and Cancer</i> , 2016, 63, 196-201.	0.8	35
123	Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. <i>Cancer</i> , 2016, 122, 230-237.	2.0	91
124	Participation in an occupational therapy referral program for children with retinoblastoma. <i>Journal of Pediatric Rehabilitation Medicine</i> , 2016, 9, 117-124.	0.3	6
125	Paediatric extracranial germ-cell tumours. <i>Lancet Oncology</i> , The, 2016, 17, e149-e162.	5.1	60
126	Clinical Trials Infrastructure as a Quality Improvement Intervention in Low- and Middle-Income Countries. <i>American Journal of Bioethics</i> , 2016, 16, 3-11.	0.5	35

#	ARTICLE	IF	CITATIONS
127	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. <i>Blood</i> , 2016, 127, 2672-2681.	0.6	1,040
128	Current treatment of Langerhans cell histiocytosis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1057-1068.	0.5	2
129	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3632-3640.	2.0	145
130	Correlation of Insurance, Race, and Ethnicity with Pathologic Risk in a Controlled Retinoblastoma Cohort. <i>Ophthalmology</i> , 2016, 123, 1817-1823.	2.5	15
131	Validation of a Pediatric Early Warning Score in Hospitalized Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients. <i>Pediatric Critical Care Medicine</i> , 2016, 17, e146-e153.	0.2	64
132	Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2016, 22, 6247-6255.	3.2	22
133	Joining forces for children with cancer in Latin America. <i>Lancet Oncology</i> , The, 2016, 17, 701-703.	5.1	4
134	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors. <i>JAMA Oncology</i> , 2016, 2, 608.	3.4	172
135	5th International ACC Symposium: Hereditary Predisposition to Childhood ACC and the Associated Molecular Phenotype. <i>Hormones and Cancer</i> , 2016, 7, 36-39.	4.9	16
136	Solid Cancers in the Premature and the Newborn: Report of Three National Referral Centers. <i>Pediatrics and Neonatology</i> , 2016, 57, 295-301.	0.3	13
137	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1364-1370.	3.2	251
138	Management and follow-up of Ewing sarcoma patients with isolated lung metastases. <i>Journal of Pediatric Surgery</i> , 2016, 51, 1067-1071.	0.8	17
139	Treatment of childhood nasopharyngeal carcinoma (cNPC) with neoadjuvant chemotherapy (NAC) and concomitant chemoradiotherapy (CCRT): Results of the Children's Oncology Group ARAR0331 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10513-10513.	0.8	7
140	Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children's Oncology Group ARAR0332 protocol.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10515-10515.	0.8	12
141	Influence of early-phase clinical trial enrollment on patterns of end-of-life care for children with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 151-151.	0.8	1
142	Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway. <i>Oncotarget</i> , 2016, 7, 56889-56903.	0.8	37
143	RNA profiling of desmoplastic small round cell tumors (DSRCTs) using next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10552-10552.	0.8	0
144	Contribution of the TP53 R337H mutation to the cancer burden in families with a proband with adrenocortical tumor.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1538-1538.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Vincristine/irinotecan upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group (COG) AHEP0731 study committee.. Journal of Clinical Oncology, 2016, 34, 10516-10516.	0.8	2
146	Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children's Oncology Group.. Journal of Clinical Oncology, 2016, 34, 10512-10512.	0.8	1
147	Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian Collaborative Study Group for Ewing Sarcoma Family Tumors-EWING1. Pediatric Blood and Cancer, 2015, 62, 1747-1753.	0.8	35
148	Ovarian function in female survivors after multimodal Ewing sarcoma therapy. Pediatric Blood and Cancer, 2015, 62, 341-345.	0.8	22
149	Impact of central surgical review in a study of malignant germ cell tumors. Journal of Pediatric Surgery, 2015, 50, 1502-1505.	0.8	5
150	Prevalence and Functional Consequence of TP53 Mutations in Pediatric Adrenocortical Carcinoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 602-609.	0.8	164
151	Ethnicity, race, and socioeconomic status influence incidence of langerhans cell histiocytosis. Pediatric Blood and Cancer, 2015, 62, 982-987.	0.8	53
152	Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal of Clinical Oncology, 2015, 33, 195-201.	0.8	111
153	Genomic landscape of paediatric adrenocortical tumours. Nature Communications, 2015, 6, 6302.	5.8	166
154	Treatment of Langerhans cell histiocytosis: it is time to learn from the past. British Journal of Haematology, 2015, 171, 148-149.	1.2	4
155	Ethnic, Racial, and Socioeconomic Disparities in Retinoblastoma. JAMA Pediatrics, 2015, 169, 1096.	3.3	86
156	Synchronous and metachronous thyroid cancer in relation to Langerhans cell histiocytosis; involvement of V600E BRAF mutation?. Pediatric Blood and Cancer, 2015, 62, 173-174.	0.8	18
157	Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis. Hematology/Oncology Clinics of North America, 2015, 29, 853-873.	0.9	91
158	Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. Journal of Clinical Oncology, 2015, 33, 3065-3073.	0.8	312
159	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. Journal of Clinical Oncology, 2015, 33, 3018-3028.	0.8	63
160	Retinoblastoma. Pediatric Clinics of North America, 2015, 62, 201-223.	0.9	102
161	Treating Childhood Cancer in Low- and Middle-Income Countries. , 2015, , 121-146.		60
162	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5564-73.	3.3	355

#	ARTICLE	IF	CITATIONS
163	Reply to G. Mangili et al and C. LhommÃ© et al. Journal of Clinical Oncology, 2014, 32, 2816-2817.	0.8	1
164	Barriers to effective treatment of pediatric solid tumors in middle-income countries: Can we make sense of the spectrum of nonbiologic factors that influence outcomes?. Cancer, 2014, 120, 112-125.	2.0	37
165	Validation of a multimodal treatment protocol for Ewing sarcoma: A report from the polish pediatric oncology group. Pediatric Blood and Cancer, 2014, 61, 2170-2174.	0.8	17
166	AsociaciÃ³n de Hemato-OncologÃ­a PediÃ¡trica de Centro AmÃ©rica (AHOPCA): A model for sustainable development in pediatric oncology. Pediatric Blood and Cancer, 2014, 61, 345-354.	0.8	76
167	Blue Toe Syndrome. JAMA Ophthalmology, 2014, 132, 654.	1.4	0
168	Adolescents and Young Adults With a "Rare" Cancer: Getting Past Semantics to Optimal Care for Patients With Germ Cell Tumors. Oncologist, 2014, 19, 689-692.	1.9	13
169	Pathologic Risk-based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation. Journal of Pediatric Hematology/Oncology, 2014, 36, e335-e340.	0.3	34
170	The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery, 2014, 4, 1326-1341.	7.7	415
171	Developmental and Adaptive Functioning in Children With Retinoblastoma: A Longitudinal Investigation. Journal of Clinical Oncology, 2014, 32, 2788-2793.	0.8	28
172	Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma. Journal of Clinical Oncology, 2014, 32, 3762-3770.	0.8	117
173	Internal hemipelvectomy in the management of pelvic Ewing sarcoma: are outcomes better than with radiation therapy?. Journal of Pediatric Surgery, 2014, 49, 1500-1504.	0.8	21
174	Delayed Diagnosis and False Relapse Due to Paternal Testosterone Use in Adrenocortical Carcinoma. Pediatrics, 2014, 133, e1772-e1776.	1.0	9
175	Multicenter study assessing tumor molecular profiles in advanced pediatric solid tumors.. Journal of Clinical Oncology, 2014, 32, 10011-10011.	0.8	3
176	Phase I study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology, 2014, 32, 10052-10052.	0.8	1
177	IVADo treatment of type II and type III pleuropulmonary blastoma (PPB): A report from the International PPB Registry.. Journal of Clinical Oncology, 2014, 32, 10060-10060.	0.8	3
178	Aggressive treatment and survival outcomes in NUT midline carcinoma (NMC) of the head and neck (HN).. Journal of Clinical Oncology, 2014, 32, 6057-6057.	0.8	7
179	Pediatric Solid Tumors. , 2014, , 1804-1848.e12.		0
180	Risk of second thyroid cancer (STC) among survivors of childhood cancer.. Journal of Clinical Oncology, 2014, 32, 10084-10084.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Postrecurrence survival for pediatric extracranial malignant germ cell tumors: A report from the Malignant Germ Cell Tumors International Collaborative (MaGIC) Group.. Journal of Clinical Oncology, 2014, 32, 10074-10074.	0.8	0
182	Analysis of somatic copy number alterations in pediatric solid tumors using array comparative genomic hybridization.. Journal of Clinical Oncology, 2014, 32, 1538-1538.	0.8	0
183	Ethnic disparities in pediatric Ewing sarcoma and osteosarcoma.. Journal of Clinical Oncology, 2014, 32, 1614-1614.	0.8	0
184	A phase II study of sirolimus and erlotinib in recurrent/refractory germ cell tumors.. Journal of Clinical Oncology, 2014, 32, TPS2638-TPS2638.	0.8	0
185	Increased risk of second malignant neoplasms (SMN) in young children with embryonal rhabdomyosarcoma (ERMS): Evidence for a cancer predisposition syndrome?. Journal of Clinical Oncology, 2014, 32, 10042-10042.	0.8	0
186	Death less than one month from diagnosis in children with cancer: A population-based analysis.. Journal of Clinical Oncology, 2014, 32, 1531-1531.	0.8	0
187	Children's Oncology Group's 2013 blueprint for research: Rare tumors. Pediatric Blood and Cancer, 2013, 60, 1016-1021.	0.8	33
188	Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical workup, and treatment for patients till the age of 18 years. Pediatric Blood and Cancer, 2013, 60, 175-184.	0.8	496
189	Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatric Blood and Cancer, 2013, 60, 1621-1625.	0.8	77
190	Pediatric sarcoma in Central America. Cancer, 2013, 119, 871-879.	2.0	45
191	Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent. Clinical Cancer Research, 2013, 19, 1740-1747.	3.2	29
192	Global challenges in pediatric oncology. Current Opinion in Pediatrics, 2013, 25, 3-15.	1.0	164
193	Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatric Blood and Cancer, 2013, 60, E19-22.	0.8	34
194	Colorimetric and Longitudinal Analysis of Leukocoria in Recreational Photographs of Children with Retinoblastoma. PLoS ONE, 2013, 8, e76677.	1.1	25
195	Socioeconomic status and incidence of pediatric embryonal tumors in the United States.. Journal of Clinical Oncology, 2013, 31, 10036-10036.	0.8	0
196	Elevated risk of second malignant neoplasms in pediatric germ cell tumor patients.. Journal of Clinical Oncology, 2013, 31, 10010-10010.	0.8	1
197	Impact of socioeconomic status on extent of disease at diagnosis and cancer and ocular outcomes in retinoblastoma: A population-based analysis.. Journal of Clinical Oncology, 2013, 31, 10011-10011.	0.8	0
198	Birth and maternal characteristics, and childhood cancer in the United States: An ecological study.. Journal of Clinical Oncology, 2013, 31, 10061-10061.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Correlation of insurance status, ethnicity, and race with pathologic risk in retinoblastoma: A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2013, 31, e17573-e17573.	0.8	0
200	Open-label, multicenter, single-arm, phase I, dose-descalation with efficacy tail extension study of vemurafenib in pediatric patients with surgically incurable and unresectable stage IIIc or IV melanoma harboring <i>BRAF</i> ^{V600} mutations (NCT01519323).. Journal of Clinical Oncology, 2013, 31, TPS9104-TPS9104.	0.8	0
201	Evaluation of the necessity of bilateral bone marrow aspirates and biopsies for the diagnosis of metastatic disease in pediatric patients with solid tumors.. Journal of Clinical Oncology, 2013, 31, 10054-10054.	0.8	0
202	Carboplatin-Associated Ototoxicity in Children With Retinoblastoma. Journal of Clinical Oncology, 2012, 30, 1034-1041.	0.8	134
203	Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer, 2012, 118, 5663-5670.	2.0	40
204	PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1097-1106.	3.3	40
205	Recent advances in the understanding of Langerhans cell histiocytosis. British Journal of Haematology, 2012, 156, 163-172.	1.2	110
206	The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Molecular and Cellular Endocrinology, 2012, 351, 37-43.	1.6	103
207	Rare Tumors of the Peripheral Nervous System. Pediatric Oncology, 2012, , 431-452.	0.5	0
208	The basics of retinoblastoma: Back to school. Pediatric Blood and Cancer, 2011, 57, 1093-1094.	0.8	7
209	Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer, 2011, 117, 197-206.	2.0	79
210	Functional Neuroimaging to Characterize Visual System Development in Children with Retinoblastoma. , 2011, 52, 2619.		16
211	The Langerhans cell histiocytosis. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 335-336.	0.7	1
212	Comparison of two methods for carboplatin dosing in children with retinoblastoma. Pediatric Blood and Cancer, 2010, 55, 47-54.	0.8	18
213	Differential features of nasopharyngeal carcinoma in children and adults: A SEER study. Pediatric Blood and Cancer, 2010, 55, 279-284.	0.8	99
214	Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. International Journal of Pediatric Otorhinolaryngology, 2010, 74, 1156-1163.	0.4	24
215	Adrenocortical Cancer in Children. , 2009, , 467-481.		0
216	THYROID CANCER IN LEBANESE CHILDREN AND ADOLESCENTS: A 15-Year Experience at a Single Institution. Pediatric Hematology and Oncology, 2009, 26, 339-447.	0.3	0

#	ARTICLE	IF	CITATIONS
217	Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments. <i>Pediatric Blood and Cancer</i> , 2009, 52, 351-356.	0.8	16
218	Development of retinoblastoma programs in Central America. <i>Pediatric Blood and Cancer</i> , 2009, 53, 42-46.	0.8	55
219	Lack of Correlation between the Histologic and Magnetic Resonance Imaging Results of Optic Nerve Involvement in Eyes Primarily Enucleated for Retinoblastoma. <i>Ophthalmology</i> , 2009, 116, 1558-1563.	2.5	50
220	Expression of the Multi-Drug Resistance Proteins and the Pregnane X Receptor in Treated and Untreated Retinoblastoma. <i>Current Eye Research</i> , 2009, 34, 386-394.	0.7	12
221	Langerhans cell histiocytosis. <i>Clinical and Translational Oncology</i> , 2008, 10, 688-696.	1.2	17
222	Sister Mary Joseph's nodule as presenting sign of a desmoplastic small round cell tumor. <i>Pediatric Blood and Cancer</i> , 2008, 50, 388-390.	0.8	11
223	Reducing irinotecan-associated diarrhea in children. <i>Pediatric Blood and Cancer</i> , 2008, 50, 201-207.	0.8	39
224	Transfer of complex frontline anticancer therapy to a developing country: The St. Jude osteosarcoma experience in Chile. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1143-1146.	0.8	18
225	Team management, twinning, and telemedicine in retinoblastoma: A 3-tier approach implemented in the first eye salvage program in Jordan. <i>Pediatric Blood and Cancer</i> , 2008, 51, 241-244.	0.8	60
226	Clofarabine in refractory Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2008, 51, 703-706.	0.8	31
227	Treating Pediatric soft tissue sarcomas in a country with limited resources: The experience of the Unidad Nacional de Oncología Pediátrica in Guatemala. <i>Pediatric Blood and Cancer</i> , 2008, 51, 760-764.	0.8	20
228	Retinoblastoma: One World, One Vision. <i>Pediatrics</i> , 2008, 122, e763-e770.	1.0	115
229	Pediatric Solid Tumors. , 2008, , 2075-2129.		4
230	Neuronal Differentiation and Synaptogenesis in Retinoblastoma. <i>Cancer Research</i> , 2007, 67, 2701-2711.	0.4	38
231	Incidence of New Tumor Formation in Patients with Hereditary Retinoblastoma Treated with Primary Systemic Chemotherapy: Is There a Preventive Effect?. <i>Ophthalmology</i> , 2007, 114, 2077-2082.e1.	2.5	17
232	Analysis of prognostic factors in ewing sarcoma family of tumors. <i>Cancer</i> , 2007, 110, 375-384.	2.0	211
233	Impact of an education program on late diagnosis of retinoblastoma in Honduras. <i>Pediatric Blood and Cancer</i> , 2007, 49, 817-819.	0.8	144
234	PET-CT in pediatric Langerhans cell histiocytosis. <i>Pediatric Radiology</i> , 2007, 37, 615-622.	1.1	101

#	ARTICLE	IF	CITATIONS
235	Treatment of retinoblastoma: Current status and future perspectives. <i>Current Treatment Options in Neurology</i> , 2007, 9, 294-307.	0.7	75
236	Trilateral retinoblastoma. , 2007, , 438-440.		0
237	Non-ocular tumors. , 2007, , 434-437.		0
238	Immunohistochemical Detection of Multidrug-Resistant Protein Expression in Retinoblastoma Treated by Primary Enucleation. , 2006, 47, 1269.		40
239	Uncommon Endocrine Tumors in Children and Adolescents. , 2006, , 775-797.		1
240	A proposal for an international retinoblastoma staging system. <i>Pediatric Blood and Cancer</i> , 2006, 47, 801-805.	0.8	225
241	Inactivation of the p53 pathway in retinoblastoma. <i>Nature</i> , 2006, 444, 61-66.	13.7	550
242	Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 15-24.	1.1	22
243	Socioeconomic Impact of Modern Multidisciplinary Management of Retinoblastoma. <i>Pediatrics</i> , 2006, 118, e331-e336.	1.0	33
244	Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 563-570.	0.8	70
245	Ewing Sarcoma Family of Tumors. , 2006, , 181-217.		6
246	Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. <i>Cancer</i> , 2005, 103, 850-857.	2.0	87
247	Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors. <i>Cancer</i> , 2005, 104, 367-373.	2.0	62
248	Biology, clinical characteristics, and management of adrenocortical tumors in children. <i>Pediatric Blood and Cancer</i> , 2005, 45, 265-273.	0.8	127
249	Use of Preclinical Models to Improve Treatment of Retinoblastoma. <i>PLoS Medicine</i> , 2005, 2, e332.	3.9	52
250	Effect on Ocular Survival of Adding Early Intensive Focal Treatments to a Two-Drug Chemotherapy Regimen in Patients With Retinoblastoma. <i>American Journal of Ophthalmology</i> , 2005, 140, 397.e1-397.e.	1.7	29
251	Pharmacological management of Ewing sarcoma family of tumours. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1257-1270.	0.9	12
252	Episcleral plaque brachytherapy for retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2004, 43, 134-139.	0.8	56

#	ARTICLE	IF	CITATIONS
253	Efficacy of combined surgery and irradiation for localized Ewings sarcoma family of tumors. <i>Pediatric Blood and Cancer</i> , 2004, 43, 229-236.	0.8	64
254	Outcome after local recurrence of osteosarcoma. <i>Cancer</i> , 2004, 100, 1928-1935.	2.0	73
255	Extranodal Rosai-Dorfman Disease in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 19-24.	0.3	61
256	Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. <i>Medical and Pediatric Oncology</i> , 2003, 40, 276-287.	1.0	179
257	Local control in childhood extremity sarcomas: Salvaging limbs and sparing function. <i>Medical and Pediatric Oncology</i> , 2003, 41, 584-587.	1.0	22
258	Treatment of metastatic retinoblastoma. <i>Ophthalmology</i> , 2003, 110, 1237-1240.	2.5	87
259	Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin. <i>Journal of Clinical Oncology</i> , 2003, 21, 2019-2025.	0.8	167
260	Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 250-255.	0.3	35
261	Ocular Preservation After 36 Gy External Beam Radiation Therapy for Retinoblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 246-249.	0.3	34
262	Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. <i>American Journal of Hematology</i> , 2002, 69, 179-184.	2.0	46
263	Survival after recurrence of Ewing Tumors. <i>Cancer</i> , 2002, 94, 561-569.	2.0	143
264	Survival after recurrence of Ewing Tumors. , 2002, 94, 561.		2
265	Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 605-611.	1.0	15
266	Primary Ewing tumor of the vertebrae: Clinical characteristics, prognostic factors, and outcome. <i>Medical and Pediatric Oncology</i> , 2001, 37, 30-35.	1.0	78
267	Neonatal alveolar rhabdomyosarcoma with skin and brain metastases. <i>Cancer</i> , 2001, 92, 1613-1620.	2.0	38
268	Hemangiopericytoma in children and infants. , 2000, 88, 198-204.		66
269	Clinical use of topoisomerase I inhibitors in anticancer treatment. <i>Medical and Pediatric Oncology</i> , 2000, 35, 385-402.	1.0	48
270	Imaging aspects of neurologic emergencies in children treated for non-CNS malignancies. <i>Pediatric Radiology</i> , 2000, 30, 558-565.	1.1	8

#	ARTICLE	IF	CITATIONS
271	Trisomy of the Long Arm of Chromosome 1 Resulting in a Dicentric Derivative (6)t(1;6) Chromosome in a Child with Myelodysplastic Syndrome Following Treatment for a Primitive Neuroectodermal Tumor. <i>Leukemia and Lymphoma</i> , 2000, 37, 213-218.	0.6	7
272	Hematologic Abnormalities and Acute Myeloid Leukemia in Children and Adolescents Administered Intensified Chemotherapy for the Ewing Sarcoma Family of Tumors. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 321-329.	1.3	43
273	Is primitive neuroectodermal tumor of the kidney a distinct entity?. , 1997, 79, 2243-2250.		89
274	Brain metastases in children with melanoma. <i>Cancer</i> , 1997, 79, 2440-2445.	2.0	25